DLA Piper Life Sciences

Mar 31, 2023

New opportunities or playing catch-up? New legislative proposals for clinical trials in the UK

By Nicholas de Lacy-Brown

Introduction Clinical trials regulation is about to get an overhaul in the UK. So promised the Medicines & Healthcare products Regulatory...

Mar 29, 2023

By Greg Bodulovic Nicholas Tyacke Tudor Filaret +1 more...

On 23 March 2023, Australia’s therapeutic goods regulator, the Therapeutic Goods Administration (TGA) published a summary of feedback...

Mar 28, 2023

By Greg Bodulovic Gareth Stokes Nicholas Tyacke +2 more...

Last week, OpenAI officially launched the next iteration of its generative AI-based natural language model, GPT-4, the processing model...

Mar 24, 2023

By Lyndsey Hudson Mary Foord-Weston

In the second of our Cortex series on Inspirational Women in Life Sciences, we are proud to feature DLA Piper’s very own Dr Lyndsey...

Mar 20, 2023

By Marco de Morpurgo Nicola Landolfi

A much-awaited extension of the MDR transition period became effective today with the publication of Regulation (EU) 2023/607 in the...

Mar 17, 2023

By Keo Shaw Bethany Hills Daniel Tobey +1 more...

On March 1, 2023, FDA’s Center for Drug Evaluation and Research (CDER) published a discussion paper on artificial intelligence (AI) in...

Mar 14, 2023

By Nicholas Tyacke Greg Bodulovic Alexandra de Zwart

Due to a complex array of legislation, regulations and codes, advertising therapeutic goods in compliance with Australian law can be a...

Mar 10, 2023

By Andrzej Balicki, Ph.D. Jolanta Dabrowicz Przemysław Matuszewski +1 more...

Download a copy of our January monthly briefing, which covers key updates and insights in the following areas: Medicinal productsClinical...

Mar 08, 2023

By Mary Foord-Weston

Beginning on International Women’s Day (IWD), DLA Piper’s Cortex blog is running a series with inspirational guest speakers to celebrate...